DMD In The Spotlight
Executive Summary
The FDA draft guidance for Duchenne’s muscular dystrophy drug development, which advocacy groups tried to push through to make sure the agency understood the complications of getting some of these drugs approved, is a good example of stakeholder interaction in the rare disease space.